AVBP
AVBPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, AVBP (AVBP) is listed under Biotechnology. Valued at $1.49B, AVBP is a small-cap name in its sector. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Market Cap
$1.49B
Beta
1.36
P/E (TTM)
—
P/E (Fwd)
-7.96
EPS (TTM)
$-3.55
EPS (Fwd)
$-3.81
ROE
-53.3%
ROA
-33.1%
Cash
$373.1M
Total Debt
$351,000
Free CF
-$89.5M
52W Change
64.0%
Annual Financials
Cash vs Debt
Where AVBP stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, AVBP finished 10.95% above its 150-day moving average ($27.94) and 17.42% above its 200-day moving average ($26.40). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AVBP overbought or oversold?
At the August 28, 2026 close, AVBP's RSI(14) was 50.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
AVBP holds $373.1M in cash against $351K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$89.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -53.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing AVBP's risk profile alongside its fundamentals and technical indicators provides a more complete picture.